Raptor Pharmaceutical Corp (RPTP) Getting Favorable News Coverage, Analysis Shows

Press coverage about Raptor Pharmaceutical Corp (NASDAQ:RPTP) has been trending positive on Wednesday, according to Accern. Accern rates the sentiment of news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Raptor Pharmaceutical Corp earned a news sentiment score of 0.27 on Accern’s scale. Accern also assigned media headlines about the biotechnology company an impact score of 46.81590342763 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

Raptor Pharmaceutical Corp (NASDAQ RPTP) opened at 9.00 on Wednesday.

ILLEGAL ACTIVITY NOTICE: “Raptor Pharmaceutical Corp (RPTP) Getting Favorable News Coverage, Analysis Shows” was originally posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this story on another website, it was illegally stolen and republished in violation of US and international copyright laws. The legal version of this story can be accessed at https://ledgergazette.com/2017/10/18/raptor-pharmaceutical-corp-rptp-receives-daily-news-sentiment-score-of-0-27.html.

About Raptor Pharmaceutical Corp

Raptor Pharmaceutical Corp. (Raptor) is a biopharmaceutical company. The Company is focused on developing and commercializing transformative treatments for people affected by diseases. Its product, PROCYSBI (cysteamine bitartrate) is a delayed-release capsules for the management of nephropathic cystinosis in adults and children of over six years.

Insider Buying and Selling by Quarter for Raptor Pharmaceutical Corp (NASDAQ:RPTP)

Receive News & Ratings for Raptor Pharmaceutical Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Raptor Pharmaceutical Corp and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply